Paz-Ares, L. G., Borghaei, H., Reck, M., Peters, S., Herbst, R. S., Kazarnowicz, A., Szczesna, A., Cubukcu, E., Kilickap, S., Ahn, J., Califano, R., Wei, Y., Srivastava, M. K., Nabet, B. Y., Graupner, V., Lin, Y., Cai, G., Brock, G., Bhatt, K., Liu, S. V. (2026). Transcriptomic analyses of molecular subsets and correlations with clinical outcomes from the phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) maintenance treatment (Tx) in extensive-stage small-cell lung cancer (ES-SCLC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8014